

# Clinical trials of picotamide

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>picotamide vs placebo</b>			
<b>Cocozza , 1995</b> n=25/25 follow-up: 24 months	picotamide 300 mg TID versus placebo	normotensive diabetic patients with asymptomatic mild or moderate nonstenotic (<50% ) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic events	Parallel groups double blind Italy
<b>Coto , 1989</b> n=20/20 follow-up: 6 months	Picotamide 900 mg / j versus Placebo	patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classification	Parallel groups double blind
<b>ADEP , 1993</b> n=1150/1154 follow-up: 18 months	Picotamide 600 mg / j versus Placebo	patients with peripheral obstructive arterial disease (stade II+)	Parallel groups double blind
<b>Neirotti , 1994</b> n=10/10 follow-up: 18 months	Picotamide 900 mg / j versus Placebo	patients with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudication for at least six months	Parallel groups double blind

More details and results :

- antiplatelets drug for cardiovascular prevention in diabetic patients at <http://www.trialresultscenter.org/go-Q220>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>

## References

### Cocozza, 1995:

Cocozza M, Picano T, Oliviero U, Russo N, Coto V, Milani M Stroke 1995;26:597-601 [7709404]

Coto V, Oliviero U, Cocozza M, Milani M Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study. J Int Med Res 1998 Aug-Sep;26:200-5 [9818786]

### Coto, 1989:

Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Coto V, Coccozza M, Oliviero U, Lucariello A, Picano T, Coto F, Cacciatore L *Angiology* 1989 Oct;40:880-5 [2679241]

**ADEP, 1993:**

Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Milani M, Longoni A, Maderna M *Br J Clin Pharmacol* 1996 Dec;42:782-5 [8971437]

Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Balsano F, Violi F *Circulation* 1993 May;87:1563-9 [8491012]

**Neirotti, 1994:**

Hemodynamic, hemorheologic, and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs. Neirotti M, Molaschi M, Ponzetto M, Macchione C, Poli L, Bonino F, Fabris F *Angiology* 1994 Feb;45:137-41 [8129189]

## 2 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>picotamide vs placebo</b>			
Coccozza , 1995 n=25/25 follow-up: 24 months	picotamide 300 mg TID versus placebo	normotensive diabetic patients with asymptomatic mild or moderate nonstenotic (<50% ) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic events	Parallel groups double blind Italy

More details and results :

- antiplatelets drug for diabetes type 2 in patients without cardiovascular disease at <http://www.trialresultscenter.org/go-Q221>
- antiplatelets drug for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q362>

## References

**Coccozza, 1995:**

Coccozza M, Picano T, Oliviero U, Russo N, Coto V, Milani M *Stroke* 1995;26:597-601 [7709404]

Coto V, Oliviero U, Coccozza M, Milani M Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study. *J Int Med Res* 1998 Aug-Sep;26:200-5 [9818786]

## 3 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
<b>picotamide vs placebo</b>			
<b>Coto , 1989</b> n=20/20 follow-up: 6 months	Picotamide 900 mg / j versus Placebo	patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classification	Parallel groups double blind
<b>ADEP , 1993</b> n=1150/1154 follow-up: 18 months	Picotamide 600 mg / j versus Placebo	patients with peripheral obstructive arterial disease (stade II+)	Parallel groups double blind
<b>Neirotti , 1994</b> n=10/10 follow-up: 18 months	Picotamide 900 mg / j versus Placebo	patients with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudication for at least six months	Parallel groups double blind

More details and results :

- antiplatelets drug for peripheral vascular diseases in all type of patient at <http://www.trialresultscenter.org/go-Q278>

## References

### **Coto, 1989:**

Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Coto V, Coccozza M, Oliviero U, Lucariello A, Picano T, Coto F, Cacciatore L *Angiology* 1989 Oct;40:880-5 [2679241]

### **ADEP, 1993:**

Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Milani M, Longoni A, Maderna M *Br J Clin Pharmacol* 1996 Dec;42:782-5 [8971437]

Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Balsano F, Violi F *Circulation* 1993 May;87:1563-9 [8491012]

### **Neirotti, 1994:**

Hemodynamic, hemorheologic, and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs. Neirotti M, Molaschi M, Ponzetto M, Macchione C, Poli L, Bonino F, Fabris F *Angiology* 1994 Feb;45:137-41 [8129189]